Under intense criticism, Gilead forsakes monopoly status for its experimental Covid-19 drug
FEATURECHINA VIA AP
The orphan designation granted by the FDA would have allowed Gilead to block lower-cost generic versions of a vital drug for seven years.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario